Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 3):iii40–iii50. doi: 10.1136/ard.61.suppl_3.iii40

Conventional treatments for ankylosing spondylitis

M Dougados, B Dijkmans, M Khan, W Maksymowych, S van der Linden, J Brandt
PMCID: PMC1766726  PMID: 12381510

Abstract

Management of ankylosing spondylitis (AS) is challenged by the progressive nature of the disease. To date, no intervention is available that alters the underlying mechanism of inflammation in AS. Currently available conventional treatments are palliative at best, and often fail to control symptoms in the long term. Current drug treatment may perhaps induce a spurious state of "disease remission," which is merely a low level of disease activity. Non-steroidal anti-inflammatory drugs are first line treatment, but over time, the disease often becomes refractory to these agents. Disease modifying antirheumatic drugs are second line treatment and may offer some clinical benefit. However, conclusive evidence of the efficacy of these drugs from large placebo controlled trials is lacking. Additionally, these drugs can cause treatment-limiting adverse effects. Intra-articular corticosteroid injection guided by arthrography, computed tomography, or magnetic resonance imaging is an effective means of reducing inflammatory back pain, but controlled studies are lacking. A controlled study has confirmed moderate but significant efficacy of intravenous bisphosphonate (pamidronate) treatment in patients with AS; further evaluation of bisphosphonate treatment is warranted. Physical therapy and exercise are necessary adjuncts to pharmacotherapy; however, the paucity of controlled data makes it difficult to identify the best way to administer these interventions. Surgical intervention may be required to support severe structural damage. Thus, for patients with AS, the future of successful treatment lies in the development of pharmacological agents capable of both altering the disease course through intervention at sites of disease pathogenesis, and controlling symptoms.

Full Text

The Full Text of this article is available as a PDF (277.6 KB).

Figure 1 .

Figure 1

Open in a new tab

Short term symptomatic efficacy of celecoxib and ketoprofen in treating ankylosing spondylitis4; p=0.0008 (treatment), *p<0.05 v placebo, †p<0.001 v placebo. Adapted and reprinted, with permission from the authors and Wiley-Liss, Inc, a subsidiary of John Wiley and Sons, Inc, from reference 4. Copyright © 2001 Wiley-Liss.

graphic file with name ar02327.f2.jpg

Open in a new tab

Figure 2. Short term symptomatic efficacy of ximoprofen in treating ankylosing spondylitis in a dose ranging study.5 Adapted and reprinted, with permission from the authors and the Scandinavian Journal of Rheumatology, from reference 5. Copyright © 1994 Taylor and Francis.

Figure 3 .

Figure 3

Open in a new tab

Effect of sulfasalazine on pain (measured on a VAS) over time among patients who completed six months of the study, by disease subgroup (ankylosing spondylitis, psoriatic arthritis, and reactive arthritis). Statistical analysis was performed using repeated measures analysis of variance.28 Adapted and reprinted, with permission from the authors and Wiley-Liss, Inc, a subsidiary of John Wiley and Sons, Inc, from reference 28. Copyright © 1995 Wiley-Liss.

Figure 4 .

Figure 4

Open in a new tab

A study of the efficacy of CT guided intra-articular triamcinolone 40 mg injections in SpA related sacroiliitis shows that a clear improvement of MRI proven sacroiliitis and inflammatory back pain occurred.50 A statistically significant improvement was measured in 25/30 (83%) patients with disease subjectively lasting 8.9 (SD 5.3) months. Sacroiliac inflammation was assessed by diagnostic MRI, and subjective back pain was assessed on a VAS (0=no pain; 10=very severe pain) before and after treatment. Adapted and reprinted, with permission from the authors and the Journal of Rheumatology, from reference 50. Copyright © 1996 Journal of Rheumatology.

Figure 5 .

Figure 5

Open in a new tab

Efficacy of prednisolone 62.5 mg versus placebo injections of sacroiliac joints in 10 patients with SpA confirms that corticosteroid injections of inflamed sacroiliac joints are effective.53 n=number of joints. This previously unpublished figure is based on data published by Dr Y Maugars et al in the British Journal of Rheumatology and is printed with the authors' permission.

Figure 6 .

Figure 6

Open in a new tab

Effects of pamidronate on clinical outcomes in AS at six months.65 Adapted and reprinted, with permission from the authors and Wiley-Liss, Inc, a subsidiary of John Wiley and Sons, Inc, from reference 65. Copyright © 2002 Wiley-Liss.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf. 1996 Mar;14(3):158–170. doi: 10.2165/00002018-199614030-00003. [DOI] [PubMed] [Google Scholar]
  2. Amor B., Dougados M., Listrat V., Menkes C. J., Dubost J. J., Roux H., Benhamou C., Blotman F., Pattin S., Paolaggi J. B. Evaluation des critères des spondylarthropathies d'Amor et de l'European Spondylarthropathy Study Group (ESSG). Une étude transversale de 2,228 patients. Ann Med Interne (Paris) 1991;142(2):85–89. [PubMed] [Google Scholar]
  3. Amor B., Dougados M., Mijiyawa M. Critères de classification des spondylarthropathies. Rev Rhum Mal Osteoartic. 1990 Feb;57(2):85–89. [PubMed] [Google Scholar]
  4. Anderson J. J., Baron G., van der Heijde D., Felson D. T., Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  5. Bellamy N., Park W., Rooney P. J. What do we know about the sacroiliac joint? Semin Arthritis Rheum. 1983 Feb;12(3):282–313. doi: 10.1016/0049-0172(83)90011-2. [DOI] [PubMed] [Google Scholar]
  6. Biasi D., Carletto A., Caramaschi P., Pacor M. L., Maleknia T., Bambara L. M. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol. 2000;19(2):114–117. doi: 10.1007/s100670050027. [DOI] [PubMed] [Google Scholar]
  7. Birnie G. G., McLeod T. I., Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut. 1981 Jun;22(6):452–455. doi: 10.1136/gut.22.6.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Black D. M., Cummings S. R., Karpf D. B., Cauley J. A., Thompson D. E., Nevitt M. C., Bauer D. C., Genant H. K., Haskell W. L., Marcus R. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535–1541. doi: 10.1016/s0140-6736(96)07088-2. [DOI] [PubMed] [Google Scholar]
  9. Braun J., Bollow M., Seyrekbasan F., Häberle H. J., Eggens U., Mertz A., Distler A., Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996 Apr;23(4):659–664. [PubMed] [Google Scholar]
  10. Calin A., Grahame R. Double-bind cross-over tiral of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J. 1974 Nov 30;4(5943):496–499. doi: 10.1136/bmj.4.5943.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clegg D. O., Reda D. J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov;42(11):2325–2329. doi: 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  12. Clegg D. O., Reda D. J., Weisman M. H., Blackburn W. D., Cush J. J., Cannon G. W., Mahowald M. L., Schumacher H. R., Jr, Taylor T., Budiman-Mak E. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2004–2012. doi: 10.1002/art.1780391209. [DOI] [PubMed] [Google Scholar]
  13. Coles L. S., Fries J. F., Kraines R. G., Roth S. H. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983 May;74(5):820–828. doi: 10.1016/0002-9343(83)91073-2. [DOI] [PubMed] [Google Scholar]
  14. Dekker-Saeys B. J., Dijkmans B. A., Tytgat G. N. Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol. 2000 Mar;27(3):723–726. [PubMed] [Google Scholar]
  15. Dougados M., Béhier J. M., Jolchine I., Calin A., van der Heijde D., Olivieri I., Zeidler H., Herman H. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001 Jan;44(1):180–185. doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  16. Dougados M., Caporal R., Doury P., Thiesce A., Pattin S., Laffez B., Amor B. A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol. 1989 Aug;16(8):1167–1169. [PubMed] [Google Scholar]
  17. Dougados M., Gueguen A., Nakache J. P., Velicitat P., Veys E. M., Zeidler H., Calin A. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999 Mar;38(3):235–244. doi: 10.1093/rheumatology/38.3.235. [DOI] [PubMed] [Google Scholar]
  18. Dougados M., Nguyen M., Caporal R., Legeais J., Bouxin-Sauzet A., Pellegri-Guegnault B., Gomeni C. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol. 1994;23(5):243–248. doi: 10.3109/03009749409103723. [DOI] [PubMed] [Google Scholar]
  19. Dougados M., Revel M., Khan M. A. Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol. 1998 Nov;12(4):717–736. doi: 10.1016/s0950-3579(98)80046-0. [DOI] [PubMed] [Google Scholar]
  20. Dougados M. Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine. 2001 Dec;68(6):557–563. doi: 10.1016/s1297-319x(01)00328-1. [DOI] [PubMed] [Google Scholar]
  21. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  22. Dunn C. J., Galinet L. A., Wu H., Nugent R. A., Schlachter S. T., Staite N. D., Aspar D. G., Elliott G. A., Essani N. A., Rohloff N. A. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther. 1993 Sep;266(3):1691–1698. [PubMed] [Google Scholar]
  23. Durez P., Horsmans Y. Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford) 2000 Feb;39(2):182–184. doi: 10.1093/rheumatology/39.2.182. [DOI] [PubMed] [Google Scholar]
  24. Eggelmeijer F., Papapoulos S. E., van Paassen H. C., Dijkmans B. A., Breedveld F. C. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol. 1994 Nov;21(11):2016–2020. [PubMed] [Google Scholar]
  25. Ferraz M. B., Tugwell P., Goldsmith C. H., Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol. 1990 Nov;17(11):1482–1486. [PubMed] [Google Scholar]
  26. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum. 1979 Apr;22(4):340–346. doi: 10.1002/art.1780220405. [DOI] [PubMed] [Google Scholar]
  27. Fox M. W., Onofrio B. M., Kilgore J. E. Neurological complications of ankylosing spondylitis. J Neurosurg. 1993 Jun;78(6):871–878. doi: 10.3171/jns.1993.78.6.0871. [DOI] [PubMed] [Google Scholar]
  28. Francis M. D., Hovancik K., Boyce R. W. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React. 1989;11(5):239–252. [PubMed] [Google Scholar]
  29. Günaydin I., Pereira P. L., Daikeler T., Mohren M., Trübenbach J., Schick F., Kanz L., Kötter I. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol. 2000 Feb;27(2):424–428. [PubMed] [Google Scholar]
  30. Hanauer S. B., Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun;6(3):192–219. doi: 10.2165/00002018-199106030-00005. [DOI] [PubMed] [Google Scholar]
  31. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000 Feb;43(2):370–377. doi: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  32. Hidding A., van der Linden S., Gielen X., de Witte L., Dijkmans B., Moolenburgh D. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res. 1994 Jun;7(2):90–96. doi: 10.1002/art.1790070208. [DOI] [PubMed] [Google Scholar]
  33. Keenan G. F. Management of complications of glucocorticoid therapy. Clin Chest Med. 1997 Sep;18(3):507–520. doi: 10.1016/s0272-5231(05)70398-1. [DOI] [PubMed] [Google Scholar]
  34. Kraag G., Stokes B., Groh J., Helewa A., Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol. 1990 Feb;17(2):228–233. [PubMed] [Google Scholar]
  35. Laasila K., Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol. 1994;23(6):338–340. doi: 10.3109/03009749409099284. [DOI] [PubMed] [Google Scholar]
  36. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A., Simon T. J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  37. Lennard L., Van Loon J. A., Weinshilboum R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 Aug;46(2):149–154. doi: 10.1038/clpt.1989.119. [DOI] [PubMed] [Google Scholar]
  38. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer. 2000 Jun 15;88(12 Suppl):3033–3037. doi: 10.1002/1097-0142(20000615)88:12+<3033::aid-cncr20>3.3.co;2-3. [DOI] [PubMed] [Google Scholar]
  39. Maksymowych W. P., Jhangri G. S., Leclercq S., Skeith K., Yan A., Russell A. S. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol. 1998 Apr;25(4):714–717. [PubMed] [Google Scholar]
  40. Maksymowych W. P., Lambert R., Jhangri G. S., Leclercq S., Chiu P., Wong B., Aaron S., Russell A. S. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol. 2001 Jan;28(1):144–155. [PubMed] [Google Scholar]
  41. Maksymowych Walter P., Jhangri Gian S., Fitzgerald Avril A., LeClercq Sharon, Chiu Peter, Yan Alex, Skeith Kenneth J., Aaron Stephen L., Homik Joanne, Davis Paul. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 2002 Mar;46(3):766–773. doi: 10.1002/art.10139. [DOI] [PubMed] [Google Scholar]
  42. Maugars Y., Mathis C., Berthelot J. M., Charlier C., Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol. 1996 Aug;35(8):767–770. doi: 10.1093/rheumatology/35.8.767. [DOI] [PubMed] [Google Scholar]
  43. Moreland L. W., Russell A. S., Paulus H. E. Management of rheumatoid arthritis: the historical context. J Rheumatol. 2001 Jun;28(6):1431–1452. [PubMed] [Google Scholar]
  44. Mukherjee D., Nissen S. E., Topol E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954–959. doi: 10.1001/jama.286.8.954. [DOI] [PubMed] [Google Scholar]
  45. Neumann V. C., Taggart A. J., Le Gallez P., Astbury C., Hill J., Bird H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1986 Apr;13(2):285–287. [PubMed] [Google Scholar]
  46. Peters N. D., Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol. 1992;21(3):134–138. doi: 10.3109/03009749209095085. [DOI] [PubMed] [Google Scholar]
  47. Peterson W. L., Cryer B. COX-1-sparing NSAIDs--is the enthusiasm justified? JAMA. 1999 Nov 24;282(20):1961–1963. doi: 10.1001/jama.282.20.1961. [DOI] [PubMed] [Google Scholar]
  48. Ralston S. H., Hacking L., Willocks L., Bruce F., Pitkeathly D. A. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis. 1989 May;48(5):396–399. doi: 10.1136/ard.48.5.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ramos-Remus C., Gomez-Vargas A., Hernandez-Chavez A., Gamez-Nava J. I., Gonzalez-Lopez L., Russell A. S. Two year followup of anterior and vertical atlantoaxial subluxation in ankylosing spondylitis. J Rheumatol. 1997 Mar;24(3):507–510. [PubMed] [Google Scholar]
  50. Richter M. B., Woo P., Panayi G. S., Trull A., Unger A., Shepherd P. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol. 1983 Jul;53(1):51–59. [PMC free article] [PubMed] [Google Scholar]
  51. Russell R. G., Croucher P. I., Rogers M. J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9 (Suppl 2):S66–S80. doi: 10.1007/pl00004164. [DOI] [PubMed] [Google Scholar]
  52. Schattenkirchner M. Indikation und Kontraindikation der systemischen Goldtherapie. Wien Klin Wochenschr Suppl. 1984;156:3–7. [PubMed] [Google Scholar]
  53. Schweitzer D. H., Oostendorp-van de Ruit M., Van der Pluijm G., Löwik C. W., Papapoulos S. E. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995 Jun;10(6):956–962. doi: 10.1002/jbmr.5650100617. [DOI] [PubMed] [Google Scholar]
  54. Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
  55. Silverstein F. E., Graham D. Y., Senior J. R., Davies H. W., Struthers B. J., Bittman R. M., Geis G. S. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995 Aug 15;123(4):241–249. doi: 10.7326/0003-4819-123-4-199508150-00001. [DOI] [PubMed] [Google Scholar]
  56. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  57. Sturrock R. D., Hart F. D. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis. 1974 Mar;33(2):129–131. doi: 10.1136/ard.33.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sweeney S., Gupta R., Taylor G., Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol. 2001 Aug;28(8):1862–1866. [PubMed] [Google Scholar]
  59. Taggart A., Gardiner P., McEvoy F., Hopkins R., Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum. 1996 Aug;39(8):1400–1405. doi: 10.1002/art.1780390819. [DOI] [PubMed] [Google Scholar]
  60. Thomson G. T., Thomson B. R., Thomson K. S., Ducharme J. S. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol. 2000 Mar;27(3):714–718. [PubMed] [Google Scholar]
  61. Van Royen B. J., De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis. 1999 Jul;58(7):399–406. doi: 10.1136/ard.58.7.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Williamson L., Illingworth H., Smith D., Mowat A. Oral quinine in ankylosing spondylitis: a randomized placebo controlled double blind crossover trial. J Rheumatol. 2000 Aug;27(8):2054–2055. [PubMed] [Google Scholar]
  63. Yamane K., Saito C., Natsuda H., Yuhara T., Akama T., Suzuki H., Kashiwagi H. Ankylosing spondylitis successfully treated with methotrexate. Intern Med. 1993 Jan;32(1):53–56. doi: 10.2169/internalmedicine.32.53. [DOI] [PubMed] [Google Scholar]
  64. van Tubergen A., Landewé R., van der Heijde D., Hidding A., Wolter N., Asscher M., Falkenbach A., Genth E., Thè H. G., van der Linden S. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2001 Oct;45(5):430–438. doi: 10.1002/1529-0131(200110)45:5<430::aid-art362>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  65. van der Heijde D., Bellamy N., Calin A., Dougados M., Khan M. A., van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997 Nov;24(11):2225–2229. [PubMed] [Google Scholar]
  66. van der Heijde D., Calin A., Dougados M., Khan M. A., van der Linden S., Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol. 1999 Apr;26(4):951–954. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES